Prime Medicine posted a net loss of USD 42.1 million for Q2 2026, narrowing from USD 52.6 million a year earlier.
R&D expense fell 19.32% to USD 33.4 million, due to lower personnel costs following a May 2025 workforce reduction and facility savings.
G&A costs dropped 16.03% to USD 11 million on lower personnel costs, reduced stock-based compensation, and lower corporate legal fees.
Cash, cash equivalents, investments, and restricted cash totaled USD 108.8 million as of June 30, 2026, down from USD 191.4 million at Dec. 31, 2025.
Pipeline and regulatory updates
FDA cleared a US IND for PM577a in Wilson disease; an IND and/or CTA for PM647 is expected in Q3 2026, with both programs’ initial data slated for 2027.
PRME•
